Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy
- 12 May 2020
- journal article
- research article
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 196 (9) , 813-820
Abstract
Purpose Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases remains poor. We aimed to explore the natural course of oligometastatic colorectal cancer and to investigate how SBRT of lung metastases can delay the progression to polymetastatic disease (PMD). Methods 107 lung oligometastases in 38 patients were treated with SBRT at a single institution. The median number of treated lesions was 2 (range 1–5). Time to PMD (ttPMD) was defined as the time from SBRT to the occurrence of >5 new metastases. Genetic biomarkers such as EGFR, KRAS, NRAS, BRAF, and microsatellite instability were investigated as predictive factors for response rates. Results Median follow-up was 28 months. At median follow-up, 7 patients were free from disease and 31 had progression: 18 patients had sequential oligometastatic disease (SOMD) and 13 polymetastatic progression. All SOMD cases received a second SBRT course. Median progression-free survival (PFS) was 7 months (range 4–9 months); median ttPMD was 25.8 months (range 12–39 months) with 1‑ and 2‑year PFS rates of 62.5% and 53.4%, respectively. 1‑ and 2‑year local PFS (LPFS) rates were 91.5% and 80%, respectively. At univariate analysis, BRAF wildtype correlated with better LPFS (p = 0.003), SOMD after primary SBRT was associated with longer cancer-specific survival (p = 0.031). Median overall survival (OS) was 39.5 months (range 26–64 months) and 2‑year OS was 71.1%. Conclusion The present results support local ablative treatment of lung metastases using SBRT in oligometastatic colorectal cancer patients, as it can delay the transition to PMD. Patients who progressed as SOMD maintained a survival advantage compared to those who developed PMD.Keywords
This publication has 41 references indexed in Scilit:
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC)Radiotherapy and Oncology, 2013
- Review and Uses of Stereotactic Body Radiation Therapy for OligometastasesThe Oncologist, 2012
- Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerCancer, 2011
- A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After ChemoradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Systems Biology Modeling of the Radiation Sensitivity Network: A Biomarker Discovery PlatformInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Analysis of Patients With Oligometastases Undergoing Two or More Curative-Intent Stereotactic Radiotherapy CoursesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic EffectAnnals of Surgical Oncology, 2005